一、停复牌 1、读客文化、奥联电子、毅昌科技：筹划控制权变更，股票停牌。 2、旭升集团：实际控制人变更为广州市人民政府，股票复牌。 二、回购 南山铝业：拟以3亿元至6亿元回购股份用于注销。 1、超声电子：拟投资10亿元进行高性能HDI印制板扩产升级技术改造项目。 三、并购重组 2、领益智造：拟8.75亿元收购立敏达35%股权。立敏达在企业级服务器热管理领域具备深厚的核心技 术积累和丰富的行业经验，其主营业务包括服务器液冷快拆连接器（UQD）、液冷歧管(Manifold)、单 相液冷散热模组（服务器液冷板及光模块冷板）、相变液冷散热模组、服务器均热板（VC和3DVC）等 热管理核心硬件产品。 四、对外投资、日常经营 2、南亚新材：拟募资不超过9亿元，用于基于AI算力的高阶高频高速覆铜板研发及产业化项目等。 3、凌云光：全资子公司拟作为基石投资者认购智谱香港联交所首次公开发行股份。 4、通宇通讯：控股子公司中洪通宇拟增资扩股引入投资者增强资本实力，满足其卫星通信产品研发及 运营支出需求。 5、三力制药：拟受让海南大学HXW2324化合物及相关专利，其用于开发阿尔茨海默病新型治疗药物的 临床前候选化合物。 1、中色 ...

每经AI快讯，12月22日，三力制药（603439）(603439.SH)公告称，公司与海南大学签署了《技术转让 (专利申请权)合同》，旨在通过整合公司产业化能力与高校研发资源，推动创新药物科研成果转化。合 同约定海南大学将其HXW2324化合物及相关专利的专利申请权转让给三力制药，转让价款总额为2亿 元，包括里程碑款0.2亿元和销售提成1.8亿元。HXW2324化合物是用于开发阿尔茨海默病 (Alzheimer'sdisease,AD)新型治疗药物的临床前候选化合物。 ...

Core Viewpoint - The news highlights the suspension of production for the Alzheimer's drug "Jiuqi Yi" (Glycyrrhizin Sodium Capsules) by Green Valley Pharmaceutical due to the expiration of its licensing approval, raising concerns among patients about when the drug will resume production [1] Group 1: Drug Status - The drug "Jiuqi Yi" is required to supplement Phase III clinical data before it can regain its licensing approval [1] - The primary inventor of the drug, researcher Geng Meiyu, confirmed that the Phase III clinical trials will continue [1] - Green Valley Pharmaceutical has not provided a clear response regarding the further development of the clinical trials for the drug [1] Group 2: Historical Context - "Jiuqi Yi" was conditionally approved for market release in November 2019, recognized as China's first original drug for treating Alzheimer's disease [1] - The approval process for the new drug took less than a year from application acceptance to approval, marking it as the first new drug approved for Alzheimer's treatment globally in nearly 20 years [1]